# Next-generation Tissue-Adhesive Endoscopic Tattoo Ink

> **NIH NIH R41** · ENDOTAT BIOTECHNOLOGIES LLC · 2024 · $343,000

## Abstract

SUMMARY
This Phase I STTR project aims to develop a lead candidate Tissue Adhesive Tattoos generation 2 (TAT2) ink
to overcome the significant limitations of current commercial inks for endoscopic marking. The new ink will
demonstrate excellent tissue retention (no diffusion), equivalent white-light contrast with Spot® Ex (the lead
commercial competitor), and no inflammatory potential. Colorectal cancer (CRC) is the second leading cause of
cancer-related deaths in the United States, as per 2023 statistics from the American Cancer Society, with an
estimated 153,020 people receiving a diagnosis of CRC, leading to 52,550 deaths from the disease. Early
identification and detection of the disease are crucial for saving lives, and more than eleven million colonoscopies
and over 6 million upper GI endoscopies are conducted in the US annually. GI tattooing is a widely used clinical
practice, and endoscopic lesion marking with tattoo ink is recommended by the US Multi-Society Task Force on
Colorectal Cancer to mark suspect regions (e.g., polyps > 1cm) with tattoo inks to facilitate identification for
longitudinal follow-up, surgery, or additional procedures at a different provider. The only FDA-approved ink,
Spot® Ex (Laborie Medical Technologies), suffers from high diffusion in tissues, which leads to poor spot
precision and localization, the generation of a fibrotic response in healthy tissues, extravasation and transmural
diffusion to other tissues, and spillage into the peritoneal space leading to peritonitis. In earlier project
development at Arizona State University (ASU), we have developed a library of TAT2 inks that demonstrate
excellent tattoo performance over the commercial tattoo ink with no systemic inflammation and toxicity over a
14-day survival study in pigs and robust shelf-life stability for up to 3 months. In this proposal, Endotat
Biotechnologies, LLC will initiate steps towards commercialization by developing an optimized, lead candidate
TAT2 ink with enhanced control over particle size (less than 0.5 polydispersity), long-term shelf stability (at least
four and up to six months), and efficient synthesis (room temperature and inert atmosphere) amenable to
eventual scale-up. Using these optimized formulations, team members at ASU will evaluate the inflammatory
response and effect on cell viability using cell-based in vitro assays and evaluate localization performance in an
ex vivo assay in fresh porcine colon tissue. The lead candidate TAT2 ink performance will be further evaluated
in live Yorkshire pigs during a long-term (6-month) survival study to performed under human clinical-equivalent
endoscopy procedure conditions at Mayo Clinic in Arizona. Quantitative measures will be used to evaluate the
ability of the ink to retain tight localization, avoid systemic and local toxicity, inflammatory response and fibrosis,
and mitigate distribution and toxicity to other organs over six months. The results of this study will establish the
found...

## Key facts

- **NIH application ID:** 11069963
- **Project number:** 1R41DK142564-01
- **Recipient organization:** ENDOTAT BIOTECHNOLOGIES LLC
- **Principal Investigator:** Kaushal Rege
- **Activity code:** R41 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $343,000
- **Award type:** 1
- **Project period:** 2024-09-23 → 2026-08-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/11069963

## Citation

> US National Institutes of Health, RePORTER application 11069963, Next-generation Tissue-Adhesive Endoscopic Tattoo Ink (1R41DK142564-01). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/11069963. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*